Brief: Basilea To Start Clinical Studies On Kinase Inhibitor

Basilea Pharmaceutica AG, Allschwil

11/02/2021 06:17

Feb 11 (Reuters) - BASILEA PHARMACEUTICA AG  BSLN.S :
    * BASILEA ACHIEVES PRECLINICAL MILESTONE IN ONCOLOGY
COLLABORATION
ON POTENTIAL FIRST-IN-CLASS KINASE INHIBITOR
    * PLANNING TO START PRECLINICAL STUDIES WITH GOAL OF FILING
FOR AN
IND, I.E. AUTHORIZATION TO EVALUATE DRUG CANDIDATE IN PHASE 1
CLINICAL STUDIES, BY END OF THIS YEAR
    * INITIATION OF CLINICAL STUDIES WITHIN NEXT TWELVE MONTHS

Source text for Eikon:  ID:nGNEBZzDw 
Further company coverage:  BSLN.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))